Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2018 17:30 ET | Source: Insmed, Inc.

FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options

--Advisory committee supports surrogate endpoint of sputum culture conversion-- --ALIS currently under FDA Priority Review; PDUFA action date set for September 28, 2018-- BRIDGEWATER, N.J., Aug. ...
August 02, 2018 07:30 ET | Source: Insmed, Inc.

Insmed Reports Second Quarter 2018 Financial Results and Provides Business Update

PDUFA (Prescription Drug User Fee Act) Action Date for ALIS (Amikacin Liposome Inhalation Suspension) Set for September 28, 2018Actively Preparing for Potential Product Launch in Early Q4 2018 ...
July 26, 2018 08:00 ET | Source: Insmed, Inc.

Insmed to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 2, 2018

BRIDGEWATER, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
June 15, 2018 08:00 ET | Source: Insmed, Inc.

Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC

BRIDGEWATER, N.J., June 15, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
June 07, 2018 08:00 ET | Source: Insmed, Inc.

Insmed to Present at Three June Conferences

BRIDGEWATER, N.J., June 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
May 22, 2018 17:15 ET | Source: Insmed, Inc.

Insmed Announces Presentations at the American Thoracic Society 2018 International Conference

Data support the benefit of treating patients with a combination of ALIS (Amikacin Liposome Inhalation Suspension) and guideline-based therapy (GBT) for the treatment of nontuberculous mycobacterial...
May 17, 2018 16:05 ET | Source: Insmed, Inc.

Insmed Appoints Leo Lee to its Board of Directors

BRIDGEWATER, N.J., May 17, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
May 16, 2018 08:00 ET | Source: Insmed, Inc.

Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC

PDUFA Action Date Set for September 28, 2018 BRIDGEWATER, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of...
May 02, 2018 07:30 ET | Source: Insmed, Inc.

Insmed Reports First Quarter 2018 Financial Results and Provides Business Update

Submitted NDA to FDA for Amikacin Liposome Inhalation Suspension (ALIS) in NTM lung disease caused by MAC; anticipates priority reviewActively preparing for potential product launch of ALIS in...
May 01, 2018 08:00 ET | Source: Insmed, Inc.

Insmed to Present at the Deutsche Bank 43rd Annual Health Care Conference

BRIDGEWATER, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right